Table 1

Baseline characteristics of patients who received adequate antibiotic monotherapy and combination therapy, and inadequate therapy
Total (n = 100) Adequate therapy (n = 65) Inadequate therapy (n = 35) Pvalue
Monotherapy (n = 32) Combination therapy (n = 33)
Age (median years, range) 59 (53–67) 60 56 61 0.24
Male gender 74 (74.0) 27 (84.4) 24 (72.7) 23 (65.7) 0.22
Underlying disease
  Hematologic malignancy 34 (34.0) 12 (37.5) 14 (42.4) 8 (22.9) 0.21
  Solid organ malignancy 23 (23.0) 8 (25.0) 12 (36.4) 3 (8.6) 0.02
  Neurologic disease 14 (14.0) 7 (21.9) 0 7 (20.0) 0.01
  Immunosuppression 22 (22.0) 6 (18.8) 10 (30.3) 6 (17.1) 0.13
  Structural lung disease 8 (8.0) 2 (6.3) 4 (12.1) 2 (5.9) 0.65
  Congestive heart failure 9 (9.0) 2 (6.3) 1 (3.0) 6 (17.1) 0.13
  Hemodialysis 10 (10.0) 2 (6.3) 1 (3.0) 7 (20.0) 0.07
  Liver cirrhosis 5 (5.0) 1 (3.1) 2 (6.1) 2 (5.7) 0.99
  Biliary disease 2 (2.0) 0 0 2 (5.7) 0.33
McCabe score <0.001
  Non-fatal 42 (42.0) 13 (40.6) 7 (21.2) 22 (62.9)
  Ultimately fatal 44 (44.0) 18 (56.3) 20 (60.6) 6 (17.1)
  Rapidly fatal 14 (14.0) 1 (3.1) 6 (18.2) 7 (20.0)
APACHE II score, median (IQR) 21 (16–26) 18.5 (13–22) 20 (17–24.5) 23 (14–27) 0.08
Pitt bacteremia score, median (IQR) 3 (1–5) 2 (0–4) 3 (2–5) 4 (2–6) 0.05
CPIS, median (IQR) 6 (5–7) 6 (5–7) 6 (5–7) 6 (5–7) 0.57
Type of pneumonia 0.01
  Community-acquired 18 (18.0) 3 (9.4) 11 (33.3) 4 (11.4)
  Healthcare-associated 19 (19.0) 8 (25.0) 6 (18.2) 5 (14.3)
  Hospital- acquired 44 (44.0) 15 (46.9) 15 (45.5) 14 (40.0)
  Ventilator-associated 19 (19.0) 6 (18.8) 1 (3.0) 12 (34.3)
Initial manifestation within 24 h 0.22
  Bacteremia without SIRS 6 (6.0) 2 (6.3) 2 (6.1) 2 (5.7)
  Sepsis 35 (35.0) 17 (53.1) 8 (24.2) 10 (28.6)
  Severe sepsis 21 (21.0) 6 (18.8) 7 (21.2) 8 (22.9)
  Septic shock 38 (38.0) 7 (21.9) 16 (48.5) 15 (42.9)
MDR-P. aeruginosa 23 (23.0) 6 (18.8) 2 (6.1) 15 (42.9) 0.001
Previous antibiotic therapy 55 (55.0) 17 (30.9) 11 (20.0) 27 (49.1) 0.009
Initial antimicrobial administration within 24 h 94 (94.0) 29 (90.6) 32 (96.9) 33 (94.3) 0.60
Total duration of therapy, median days (IQR) 14 (8–21) 15 (9–19) 14 (8–22) 14 (7–21) 0.71
Total length of hospital stay, median days (IQR) 37.5 (19–75) 39 (19–94) 28 (13–60) 52 (26–82) 0.10
Length of hospital stay before bacteremia, median days (IQR) 12.5 (0–39) 9 (0–29.5) 0 (0–19.5) 29 (9–59) 0.005
Length of hospital stay after bacteremia, median days (IQR) 16.5 (7–36.5) 18.5 (10.8-52.5) 16 (6.5-34) 17 (7–33) 0.21
Overall mortality
  7-day mortality 21 (21.0) 5 (15.6) 6 (18.2) 10 (28.6) 0.382
  14-day mortality 30 (30.0) 8 (25.0) 6 (18.2) 16 (45.7) 0.035
  28-day mortality 51 (51.0) 17 (53.1) 10 (30.3) 24 (68.6) 0.01

Data are presented as number (%) unless otherwise specified.

IQR = interquartile range,CPIS = Clinical Pulmonary Infection Score, MDR = multidrug-resistant.

Park et al.

Park et al. BMC Infectious Diseases 2012 12:308   doi:10.1186/1471-2334-12-308

Open Data